Following pharmacological inhibition or genetic abrogation of the TRPM8 receptor, we could revert PCNA expression to levels comparable to those observed in the untreated samples, in both the colorectal cancer cell lines examined (Figure 4A and Figure S2A), while no difference was observed in HCEC-1CT cells upon iPolyP challenge (Supplementary Figure S3A). This evidence concerns the gene PCNA and colorectal cancer.